Skip to main content
OpenTrials
Completed

NCT Number: NCT05614791

Evaluation of Pediatric Measles Cases in 2019: Single-Center Experience

Measles, can be prevented and eliminated by vaccination, is a highly contagious viral disease that can lead to serious complications, disability, and death. As a result of the World Health Organization (WHO) and United Nations International Children's Emergency Fund (UNICEF) strategic plans, the annual global incidence of measles decreased by 75% over the period 2000-2015, and the estimated global mortality rate fell by 73%. For the current 2019 period, the European and the Eastern Mediterranean Region has recorded respectively more than two-fold and 1.5-fold increase in reported measles cases. As it is known, no specific antiviral treatment exists for the measles virus therefore, vaccination is still the most effective method of preventing disease.

The aim of this study was to evaluate the measles cases in districts where the refugees live quite intensely.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Measles Infections Mononegavirales Infections Morbillivirus Infections Paramyxoviridae Infections RNA Virus Infections Virus Diseases

Age range

1 month–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Esenler Maternity and Child Health Hospital, Istanbul, Esenler, Turkey (Türkiye)

Loading trial locations.

About this study

Measles, can be prevented and eliminated by vaccination, is a highly contagious viral disease that can lead to serious complications, disability, and death. As a result of the World Health Organization (WHO) and United Nations International Children's Emergency Fund (UNICEF) strategic plans, the annual global incidence of measles decreased by 75% over the period 2000-2015, and the estimated global mortality rate fell by 73%. For the current 2019 period, the European and the Eastern Mediterranean Region has recorded respectively more than two-fold and 1.5-fold increase in reported measles cases. As it is known, no specific antiviral treatment exists for the measles virus therefore, vaccination is still the most effective method of preventing disease.

The aim of this study was to evaluate the measles cases in districts where the refugees live quite intensely.

This retrospective study was consecutively enrolled children who were considered as suspicious measles case according to with clinical features and attended in Esenler Gynecology and Pediatrics Hospital Pediatric Clinic between 01 January-30 June 2019.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The suspicious case of measles
  • Measles/Rubella Case Notification and Laboratory request and result form and Measles/ Rubella Case Study form must be filled
  • Accept the informed consent form
  • Positive Measles Ig M and Measles Ig G laboratory test

Exclusion criteria

  • Rejected the informed consent form

Treatment and study plan

Primary outcomes

  1. Evaluate the effect of measles vaccination status on symptom duration

    Time frame: baseline

    compare the groups symptom durations (day) who fully, partly or not vaccinated

  2. Evaluate the effect of vitamin A treatment on symptom duration

    Time frame: in the first month after the first symptom observed

    compare the groups symptom durations (day) who get or not get vitamin A treatment

Secondary outcomes

  1. Evaluate the effect of measles vaccination status on leucocyte count

    Time frame: baseline

    compare the groups leucocyte count who fully, partly or not vaccinated

  2. Evaluate the effect of vitamin A treatment on leucocyte count

    Time frame: baseline

    compare the groups leucocyte count who get or not get vitamin A treatment

Other outcomes

  1. Evaluate the effect of measles vaccination status on cost of measles cases

    Time frame: in the first month after the first symptom observed

    compare the groups costs (Turkish Lira) who fully, partly or not vaccinated

  2. Evaluate the effect of vitamin A treatment on cost of measles cases

    Time frame: in the first month after the first symptom observed

    compare the groups costs (Turkish Lira) who get or not get vitamin A treatment

Sponsors and collaborators

Lead sponsor

Marmara University

Other

Registry information

Important dates

Study start
2019
Primary completion
2019
Study completion
2020
First posted
Nov 14, 2022
Registry last updated
Nov 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.